{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:29:30Z","timestamp":1781245770072,"version":"3.54.1"},"reference-count":176,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Primary Sj\u00f6gren\u2019s Syndrome (pSS) is a complex autoimmune disorder characterized by exocrine gland dysfunction, leading to dry eyes and mouth. Despite growing interest in biologic therapies for pSS, FDA approval has proven challenging due to trial complications. This review addresses the absence of a molecular-target-based approach to biologic therapy development and highlights novel research on drug targets and clinical trials. A literature search identified potential pSS treatment targets and recent advances in molecular understanding. Overlooking extraglandular symptoms like fatigue and depression is a notable gap in trials. Emerging biologic agents targeting cytokines, signal pathways, and immune responses have proven efficacy. These novel therapies could complement existing methods for symptom alleviation. Improved grading systems accounting for extraglandular symptoms are needed. The future of pSS treatment may involve gene, stem-cell, and tissue-engineering therapies. This narrative review offers insights into advancing pSS management through innovative biologic interventions.<\/jats:p>","DOI":"10.3389\/fphar.2024.1377055","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T04:31:55Z","timestamp":1715920315000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Emerging biologic frontiers for Sjogren\u2019s syndrome: Unveiling novel approaches with emphasis on extra glandular pathology"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiao Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maierhaba","family":"Maitiyaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue Qiang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui Lian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/art.30236","article-title":"B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sj\u00f6gren\u2019s syndrome: a double-blind, placebo-controlled study","volume":"63","author":"Abdulahad","year":"2011","journal-title":"Arthritis rheumatism"},{"key":"B2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7326\/0003-4819-98-2-155","article-title":"Sj\u00f6gren\u2019s syndrome: association of anti-ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity","volume":"98","author":"Alexander","year":"1983","journal-title":"Ann. Intern. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaut.2010.07.005","article-title":"Aberrant expression of CD6 on B-cell subsets from patients with Sj\u00f6gren\u2019s syndrome","volume":"35","author":"Alonso","year":"2010","journal-title":"J. Autoimmun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","year":"2000","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/1529-0131(200111)44:11<2633::aid-art443>3.0.co;2-9","article-title":"Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sj\u00f6gren\u2019s syndrome","volume":"44","author":"Amft","year":"2001","journal-title":"Arthritis rheumatism"},{"key":"B6","first-page":"199","article-title":"The spectrum of benign to malignant lymphoproliferation in Sj\u00f6gren\u2019s syndrome","volume":"10","author":"Anderson","year":"1972","journal-title":"Clin. Exp. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s10753-020-01322-w","article-title":"Inhibition of JAK-STAT signaling by baricitinib reduces interferon-gamma-induced CXCL10 production in human salivary gland ductal cells","volume":"44","author":"Aota","year":"2021","journal-title":"Inflammation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/1529-0131(200008)43:8<1756::AID-ANR12>3.0.CO;2-H","article-title":"Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structure in Sj\u00f6gren\u2019s syndrome salivary glands","volume":"43","author":"Azuma","year":"2000","journal-title":"Arthritis rheumatism"},{"key":"B9","first-page":"269","article-title":"Role of cytokines in the destruction of acinar structure in Sjogren\u2019s syndrome salivary glands","volume":"77","author":"Azuma","year":"1997","journal-title":"Lab. Invest."},{"key":"B10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren\u2019s syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1136\/annrheumdis-2021-222053","article-title":"Pilot study of baricitinib for active Sjogren\u2019s syndrome","volume":"81","author":"Bai","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/art.21062","article-title":"Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid\u2010like structures in Sj\u00f6gren\u2019s syndrome","volume":"52","author":"Barone","year":"2005","journal-title":"Arthritis & Rheumatism."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/rheumatology\/keaa670","article-title":"Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sjogren\u2019s syndrome","volume":"60","author":"Barrera","year":"2021","journal-title":"Rheumatol. Oxf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/art.41610","article-title":"Integrative analysis reveals a molecular stratification of systemic autoimmune diseases","volume":"73","author":"Barturen","year":"2021","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nrrheum.2018.23","article-title":"Moving towards a molecular taxonomy of autoimmune rheumatic diseases","volume":"14","author":"Barturen","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sj\u00f6gren\u2019s syndrome: a possible etiopathogenic mechanism","volume":"52","author":"B\u00e5ve","year":"2005","journal-title":"Arthritis & Rheumatism."},{"key":"B17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a target for therapeutic type I and II monoclonal antibodies","volume":"47","author":"Beers","year":"2010","journal-title":"Semin. Hematol."},{"key":"B18","first-page":"55","article-title":"Sj\u00f6gren\u2019s syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology","volume":"22","author":"Bernacchi","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2005.01.017","article-title":"Xerosis in primary Sj\u00f6gren syndrome: immunohistochemical and functional investigations","volume":"39","author":"Bernacchi","year":"2005","journal-title":"J. dermatological Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/art.42789","article-title":"Association of combined anti-ro52\/TRIM21 and anti-ro60\/SSA antibodies with increased sj\u00f6gren disease severity through interferon pathway activation","volume":"76","author":"Bettacchioli","year":"2023","journal-title":"Arthritis Rheumatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/rheumatology\/kex490","article-title":"Systemic interferon type I and type II signatures in primary Sjogren\u2019s syndrome reveal differences in biological disease activity","volume":"57","author":"Bodewes","year":"2018","journal-title":"Rheumatol. Oxf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2019.00312","article-title":"Fatigue in sjogren\u2019s syndrome: a search for biomarkers and treatment targets","volume":"10","author":"Bodewes","year":"2019","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary sj\u00f6gren\u2019s syndrome: rituximab for symptomatic fatigue and oral dryness in primary SS","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"B25","first-page":"1356","article-title":"Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes","volume":"41","author":"Brignole","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of sj\u00f6gren\u2019s syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2017","journal-title":"Arthritis Care Res. Hob."},{"key":"B27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.15698\/mic2019.10.693","article-title":"Gut microbial metabolites in depression: understanding the biochemical mechanisms","volume":"6","author":"Caspani","year":"2019","journal-title":"Microb. Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5009\/gnl16365","article-title":"Extrahepatic manifestations of primary biliary cholangitis","volume":"11","author":"Chalifoux","year":"2017","journal-title":"Gut Liver"},{"key":"B29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12016-019-08743-y","article-title":"JAK inhibitors suppress innate epigenetic reprogramming: a promise for patients with sj\u00f6gren\u2019s syndrome","volume":"58","author":"Charras","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.3389\/fimmu.2019.02814","article-title":"JAK inhibitors and oxidative stress control","volume":"10","author":"Charras","year":"2019","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"731122","DOI":"10.3389\/fphar.2021.731122","article-title":"Rituximab therapy for primary sj\u00f6gren\u2019s syndrome","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3315\/jdcr.2015.1207","article-title":"Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sj\u00f6gren syndrome. Report of two cases and review of literature","volume":"9","author":"Chimenti","year":"2015","journal-title":"J. dermatological case Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.4317\/jced.59891","article-title":"Effectiveness of pharmacological interventions for Sjogren syndrome - a systematic review","volume":"15","author":"Choudhary","year":"2023","journal-title":"J. Clin. Exp. Dent."},{"key":"B34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/cei.12644","article-title":"Interleukin-36\u03b1 axis is modulated in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"181","author":"Ciccia","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/annrheumdis-2012-202754","article-title":"Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren\u2019s syndrome","volume":"72","author":"Ciccia","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/keu004","article-title":"Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"53","author":"Ciccia","year":"2014","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/ard.2011.154013","article-title":"Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sj\u00f6gren\u2019s syndrome","volume":"71","author":"Ciccia","year":"2012","journal-title":"Ann. Rheumatic Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41584-020-0380-x","article-title":"CD40 blockade shows promise in pSS trial","volume":"16","author":"Clarke","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20\u2013mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.ypmed.2011.12.019","article-title":"n\u22123 fatty acids prevent impairment of neurogenesis and synaptic plasticity in B-cell activating factor (BAFF) transgenic mice","volume":"54","author":"Crupi","year":"2012","journal-title":"Prev. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.biopsych.2009.12.008","article-title":"Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice","volume":"67","author":"Crupi","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/art.11199","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results","volume":"49","author":"Cummins","year":"2003","journal-title":"Arthritis rheumatism"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann. Rheumatic Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s00296-019-04354-0","article-title":"Fatigue in primary Sj\u00f6gren\u2019s syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study","volume":"39","author":"Davies","year":"2019","journal-title":"Rheumatol. Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1136\/annrheumdis-2015-208304","article-title":"Towards personalised treatment in primary Sj\u00f6gren\u2019s syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment","volume":"75","author":"Delli","year":"2016","journal-title":"Ann. Rheumatic Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/biom11020251","article-title":"The role of interferons in the pathogenesis of Sj\u00f6gren\u2019s syndrome and future therapeutic perspectives","volume":"11","author":"Del Papa","year":"2021","journal-title":"Biomolecules"},{"key":"B47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern Med."},{"key":"B48","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sjogren\u2019s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"B49","first-page":"228","article-title":"Ianalumab (VAY736) in primary Sjogren\u2019s syndrome: assessing disease activity using multi-modal ultrasound","volume":"126","author":"Diekhoff","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1046\/j.1365-2249.2002.01752.x","article-title":"CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sj\u00f6gren\u2019s syndrome patients indicating their intrinsic activation","volume":"127","author":"Dimitriou","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"684999","DOI":"10.3389\/fimmu.2021.684999","article-title":"The multiple roles of B cells in the pathogenesis of sjogren\u2019s syndrome","volume":"12","author":"Du","year":"2021","journal-title":"Front. Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/rheumatology\/keaa257","article-title":"Refining myositis associated with primary Sj\u00f6gren\u2019s syndrome: data from the prospective cohort ASSESS","volume":"60","author":"Felten","year":"","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B55","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1183\/16000617.0011-2016","article-title":"Pulmonary manifestations of Sj\u00f6gren\u2019s syndrome","volume":"25","author":"Flament","year":"2016","journal-title":"Eur. Respir. Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaci.2017.07.041","article-title":"Role of the IL-12\/IL-35 balance in patients with Sj\u00f6gren syndrome","volume":"142","author":"Fogel","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sj\u00f6gren\u2019s syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","article-title":"Treatment of Sj\u00f6gren\u2019s syndrome: current therapy and future directions","volume":"60","author":"Fox","year":"2021","journal-title":"Rheumatology."},{"key":"B60","first-page":"199","article-title":"Double anti-B cell and anti-BAFF targeting for the treatment of primary Sj\u00f6gren\u2019s syndrome","volume":"37","author":"Gandolfo","year":"2019","journal-title":"Clin. Exp. Rheumatology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1593\/tlo.10172","article-title":"Interleukin 22 signaling promotes cell growth in mantle cell lymphoma","volume":"4","author":"Gelebart","year":"2011","journal-title":"Transl. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s12016-017-8639-y","article-title":"Cutaneous and mucosal manifestations of Sj\u00f6gren\u2019s syndrome","volume":"53","author":"Generali","year":"2017","journal-title":"Clin. Rev. Allergy & Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13075-017-1284-2","article-title":"Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling","volume":"19","author":"Giltiay","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sj\u00f6gren\u2019s syndrome: results in 78 patients of the AutoImmune and Rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann. Rheumatic Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/art.40425","article-title":"Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated sjogren\u2019s syndrome: post hoc analyses from the EMBODY trials","volume":"70","author":"Gottenberg","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B66","first-page":"1089","article-title":"Salivary and serum interleukin 6 in primary Sj\u00f6gren\u2019s syndrome","volume":"24","author":"Grisius","year":"1997","journal-title":"J. Rheumatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/odi.13062","article-title":"World Workshop on Oral Medicine VII: immunobiologics for salivary gland disease in Sj\u00f6gren\u2019s syndrome: a systematic review","volume":"25","author":"Gueiros","year":"2019","journal-title":"Oral Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaut.2012.01.016","article-title":"Role of Toll-like receptors in primary Sj\u00f6gren\u2019s syndrome with a special emphasis on B-cell maturation within exocrine tissues","volume":"39","author":"Guerrier","year":"2012","journal-title":"J. Autoimmun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e000382","DOI":"10.1136\/lupus-2020-000382","article-title":"Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus","volume":"7","author":"Han","year":"2020","journal-title":"Lupus Sci. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/ard.2007.071563","article-title":"Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sj\u00f6gren syndrome: a randomised controlled trial","volume":"67","author":"Hartkamp","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/RHU.0000000000000210","article-title":"Refractory primary Sj\u00f6gren syndrome successfully treated with bortezomib","volume":"21","author":"Jakez-Ocampo","year":"2015","journal-title":"J. Clin. rheumatology Pract. Rep. rheumatic Musculoskelet. Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/rheumatology\/kez335","article-title":"Unique Sj\u00f6gren\u2019s syndrome patient subsets defined by molecular features","volume":"59","author":"James","year":"2020","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B74","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.medcli.2019.01.016","article-title":"Clinical profile and associated factors of pulmonary involvement in primary Sj\u00f6gren\u2019s syndrome","volume":"153","author":"Jin","year":"2019","journal-title":"Med. Cl\u00ednica"},{"key":"B75","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10067-005-1104-y","article-title":"Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sj\u00f6gren\u2019s syndrome, and Wegener\u2019s granulomatosis","volume":"24","author":"Kamali","year":"2005","journal-title":"Clin. Rheumatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/rheumatology\/keq158","article-title":"Psychopathological and personality features in primary Sjogren\u2019s syndrome--associations with autoantibodies to neuropeptides","volume":"49","author":"Karaiskos","year":"2010","journal-title":"Rheumatology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/sji.12520","article-title":"Expression of toll-like receptors in peripheral blood mononuclear cells of patients with primary sj\u00f6gren\u2019s syndrome","volume":"85","author":"Karlsen","year":"2017","journal-title":"Scand. J. Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000446780","article-title":"Abberant sudomotor functions in sj\u00f6gren\u2019s syndrome: comparable study with atopic dermatitis on dry skin manifestation","volume":"51","author":"Katayama","year":"2016","journal-title":"Curr. problems dermatology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12016-007-8011-8","article-title":"T lymphocytes in Sjogren\u2019s syndrome: contributors to and regulators of pathophysiology","volume":"32","author":"Katsifis","year":"2007","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"102335","DOI":"10.1016\/j.jaut.2019.102335","article-title":"Autoimmune epithelitis (Sj\u00f6gren\u2019s syndrome); the impact of metabolic status of glandular epithelial cells on auto-immunogenicity","volume":"104","author":"Katsiougiannis","year":"2019","journal-title":"J. Autoimmun."},{"key":"B82","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3899\/jrheum.100486","article-title":"Activation of the interferon pathway in peripheral blood of patients with Sj\u00f6gren\u2019s syndrome","volume":"38","author":"Kimoto","year":"2011","journal-title":"J. Rheumatology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3109\/14397595.2013.861333","article-title":"Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: a case report","volume":"26","author":"Komai","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.medj.2022.05.002","article-title":"Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases","volume":"3","author":"Korsunsky","year":"2022","journal-title":"Med. (New York, NY)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00296-014-3008-0","article-title":"Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sj\u00f6gren\u2019s syndrome compared to systemic lupus erythematosus and rheumatoid arthritis","volume":"34","author":"Kotsis","year":"2014","journal-title":"Rheumatol. Int."},{"key":"B86","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-3083.2007.02049.x","article-title":"B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sj\u00f6gren\u2019s syndrome","volume":"67","author":"Lavie","year":"2008","journal-title":"Scand. J. Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12026-013-8423-x","article-title":"Rationale for treating primary Sj\u00f6gren\u2019s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab)","volume":"56","author":"Le Dantec","year":"2013","journal-title":"Immunol. Res."},{"key":"B89","first-page":"234","article-title":"Predictive significance of CCL21 and CXCL13 levels in the minor salivary glands of patients with Sj\u00f6gren\u2019s syndrome","volume":"35","author":"Lee","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202863","article-title":"Health-related utility values of patients with primary Sj\u00f6gren\u2019s syndrome and its predictors","volume":"73","author":"Lendrem","year":"2014","journal-title":"Ann. Rheumatic Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41413-019-0067-6","article-title":"Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology","volume":"7","author":"Li","year":"2019","journal-title":"Bone Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1177\/0022034519837240","article-title":"Targeted TNF-\u03b1 overexpression drives salivary gland inflammation","volume":"98","author":"Limaye","year":"2019","journal-title":"J. Dent. Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"131","DOI":"10.55563\/clinexprheumatol\/fp741f","article-title":"Serum CXCL13, BAFF, IL-21 and IL-22 levels are related to disease activity and lymphocyte profile in primary Sj\u00f6gren\u2019s syndrome","volume":"39","author":"Loureiro-Amigo","year":"2021","journal-title":"Clin. Exp. Rheumatology"},{"key":"B94","first-page":"291","article-title":"Interstitial lung disease in Sj\u00f6gren\u2019s syndrome: a clinical review","volume":"126","author":"Luppi","year":"2020","journal-title":"Clin. Exp. Rheumatology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"703079","DOI":"10.3389\/fimmu.2021.703079","article-title":"Understanding fatigue in Sj\u00f6gren\u2019s syndrome: outcome measures, biomarkers and possible interventions","volume":"12","author":"M\u00e6land","year":"2021","journal-title":"Front. Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1002\/art.23073","article-title":"Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sj\u00f6gren\u2019s syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development","volume":"56","author":"Manoussakis","year":"2007","journal-title":"Arthritis & Rheumatism."},{"key":"B97","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/1529-0131(199902)42:2<229::AID-ANR4>3.0.CO;2-X","article-title":"Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sj\u00f6gren\u2019s syndrome","volume":"42","author":"Manoussakis","year":"1999","journal-title":"Arthritis rheumatism"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e163030","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI insight"},{"key":"B99","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMc1804598","article-title":"Primary sjogren\u2019s syndrome","volume":"379","author":"Mariette","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren\u2019s Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B101","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"","journal-title":"Ann. Rheumatic Dis."},{"key":"B102","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40265-018-0917-3","article-title":"Tildrakizumab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"B104","first-page":"311","article-title":"Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line","volume":"18","author":"Matsumura","year":"2000","journal-title":"Clin. Exp. Rheumatol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1093\/rheumatology\/keac111","article-title":"Ruxolitinib inhibits IFN\u03b3-stimulated Sj\u00f6gren\u2019s salivary gland MSC HLA-DR expression and chemokine-dependent T cell migration","volume":"61","author":"McCoy","year":"2022","journal-title":"Rheumatol. Oxf."},{"key":"B106","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","article-title":"Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sj\u00f6gren\u2019s syndrome treated with rituximab","volume":"71","author":"Meiners","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sjogren\u2019s syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B109","doi-asserted-by":"publisher","first-page":"105413","DOI":"10.1016\/j.jbspin.2022.105413","article-title":"Identifying clinical, biological, and quality of life variables associated with depression, anxiety, and fatigue in pSS and sicca syndrome patients: a prospective single-centre cohort study","volume":"89","author":"Miglianico","year":"2022","journal-title":"Jt. Bone Spine"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0714.2004.00264.x","article-title":"Sj\u00f6gren\u2019s syndrome: the diagnostic potential of early oral manifestations preceding hyposalivation\/xerostomia","volume":"34","author":"Mignogna","year":"2005","journal-title":"J. oral pathology Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3899\/jrheum.080234","article-title":"Association of severe inflammatory polyarthritis in primary Sj\u00f6gren\u2019s syndrome: clinical, serologic, and HLA analysis","volume":"36","author":"Mohammed","year":"2009","journal-title":"J. Rheumatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/03009742.2018.1469164","article-title":"Anti-citrullinated protein antibodies and arthritis in Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis","volume":"48","author":"Molano-Gonz\u00e1lez","year":"2019","journal-title":"Scand. J. Rheumatol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/ard.2007.077891","article-title":"Lack of efficacy of etanercept in Sj\u00f6gren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation","volume":"67","author":"Moutsopoulos","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B115","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren\u2019s syndrome: a systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren\u2019s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren\u2019s related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J. Autoimmun."},{"key":"B117","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/art.23214","article-title":"Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sj\u00f6gren\u2019s syndrome: findings in humans and mice","volume":"58","author":"Nguyen","year":"2008","journal-title":"Arthritis & Rheumatism."},{"key":"B118","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/cei.13602","article-title":"Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice","volume":"205","author":"Nocturne","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary Sjogren syndrome","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e003464","DOI":"10.1136\/rmdopen-2023-003464","article-title":"Efficacy of daratumumab in refractory primary Sj\u00f6gren disease","volume":"9","author":"Nocturne","year":"2023","journal-title":"RMD Open"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/art.1780390816","article-title":"Cytokine messenger rna expression in the labial salivary glands of patients with Sj\u00f6gren\u2019s syndrome","volume":"39","author":"Ohyama","year":"1996","journal-title":"Arthritis & Rheumatism"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e000066","DOI":"10.1136\/rmdopen-2015-000066","article-title":"ACPA-positive primary Sj\u00f6gren\u2019s syndrome: true primary or rheumatoid arthritis-associated Sj\u00f6gren\u2019s syndrome?","volume":"1","author":"Payet","year":"2015","journal-title":"RMD Open"},{"key":"B123","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/rheumatology\/32.7.609","article-title":"The arthropathy of Sj\u00f6gren\u2019s syndrome","volume":"32","author":"Pease","year":"1993","journal-title":"Br. J. rheumatology"},{"key":"B124","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.58.7.423","article-title":"Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both)","volume":"58","author":"Pertovaara","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"B125","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.brs.2020.12.004","article-title":"Transcranial direct current stimulation for fatigue in patients with Sjogren\u2019s syndrome: a randomized, double-blind pilot study","volume":"14","author":"Pinto","year":"2021","journal-title":"Brain Stimul."},{"key":"B126","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren\u2019s syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis & Rheumatology"},{"key":"B127","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/rheumatology\/kex375","article-title":"The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren\u2019s Syndrome","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B129","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann. Rheumatic Dis."},{"key":"B130","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sjogren\u2019s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B131","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00005792-200207000-00004","article-title":"Primary Sj\u00f6gren syndrome: hematologic patterns of disease expression","volume":"81","author":"Ramos-Casals","year":"2002","journal-title":"Med. Baltim."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3389\/fimmu.2018.01200","article-title":"Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in primary Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus","volume":"9","author":"Rietveld","year":"2018","journal-title":"Front. Immunol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/rheumatology\/kep104","article-title":"Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren\u2019s syndrome","volume":"48","author":"Rihl","year":"2009","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1136\/annrheumdis-2019-216588","article-title":"Salivary gland epithelial cells from patients with Sj\u00f6gren\u2019s syndrome induce B-lymphocyte survival and activation","volume":"79","author":"Rivi\u00e8re","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B135","first-page":"632","article-title":"Cutaneous manifestations of primary Sj\u00f6gren\u2019s syndrome are underestimated","volume":"22","author":"Roguedas","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet London, Engl."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00296-012-2572-4","article-title":"Follow-up of primary Sjogren\u2019s syndrome patients presenting positive anti-cyclic citrullinated peptides antibody","volume":"33","author":"Ryu","year":"2013","journal-title":"Rheumatol. Int."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int. Rev. Immunol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"B141","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American college of rheumatology\/European league against rheumatism classification criteria for primary sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"key":"B143","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/cei.13242","article-title":"Activation of Toll-like receptor 7 signaling in labial salivary glands of primary Sj\u00f6gren\u2019s syndrome patients","volume":"196","author":"Shimizu","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00418-010-0735-5","article-title":"Expression of pro-inflammatory TACE-TNF-\u03b1-amphiregulin axis in Sj\u00f6gren\u2019s syndrome salivary glands","volume":"134","author":"Sisto","year":"2010","journal-title":"Histochem. Cell Biol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary Sjogren\u2019s syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat. Commun."},{"key":"B146","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/annrheumdis-2023-eular.234","article-title":"OP0143 efficacy and safety of Dazodalibep (Vib4920\/Hzn4920) in subjects with Sj\u00f6gren\u2019s syndrome: a phase 2, randomized, double-blind, placebo-controlled, proof of concept study","volume":"82","author":"St","year":"2023","journal-title":"Ann. Rheumatic Dis."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary sj\u00f6gren\u2019s syndrome: results from a phase II randomized, double-blind, placebo-controlled trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"key":"B148","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/art.37874","article-title":"Notice of retraction of two articles (\"Infliximab in patients with primary Sjogren\u2019s syndrome: a pilot study\" and \"Infliximab in patients with primary Sjogren\u2019s syndrome: one-year followup\")","volume":"65","author":"Steinfeld","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B149","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatology"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren\u2019s syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B152","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1002\/mco2.156","article-title":"The molecular pathophysiology of depression and the new therapeutics","volume":"3","author":"Tian","year":"","journal-title":"MedComm"},{"key":"B153","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1002\/art.38129","article-title":"Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"65","author":"Tob\u00f3n","year":"2013","journal-title":"Arthritis rheumatism"},{"key":"B154","doi-asserted-by":"publisher","first-page":"15502","DOI":"10.1038\/s41598-019-51616-9","article-title":"Differential treatments based on drug-induced gene expression signatures and longitudinal systemic lupus erythematosus stratification","volume":"9","author":"Toro-Dom\u00ednguez","year":"2019","journal-title":"Sci. Rep."},{"key":"B155","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s42358-022-00267-y","article-title":"Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary Sj\u00f6gren syndrome: results of an epidemiologic systematic review\/meta-analysis and a consensus guideline from the Brazilian society of rheumatology (hepatic, gastrointestinal and pancreatic)","volume":"62","author":"Trevisani","year":"2022","journal-title":"Adv. Rheumatology Lond. Engl."},{"key":"B156","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/mr\/roac011","article-title":"Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjogren\u2019s syndrome associated with rheumatoid arthritis: findings from an open-label, multicentre, 1-year, prospective study: the ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren\u2019s Syndrome Endocrinopathy) and ROSE II trials","volume":"33","author":"Tsuboi","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren\u2019s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatology"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/ard.2004.031781","article-title":"Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sj\u00f6gren\u2019s syndrome compared with non-Sj\u00f6gren\u2019s sicca syndrome","volume":"64","author":"van Woerkom","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"B159","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1093\/rheumatology\/kez004","article-title":"T cells in primary Sj\u00f6gren\u2019s syndrome: targets for early intervention","volume":"60","author":"Verstappen","year":"","journal-title":"Rheumatology"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/art.40165","article-title":"Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary sj\u00f6gren\u2019s syndrome","volume":"69","author":"Verstappen","year":"2017","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"key":"B161","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial\u2013immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"","journal-title":"Nat. Rev. Rheumatol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat. Rev. Gastroenterology hepatology"},{"key":"B163","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/icb.2011.111","article-title":"BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus","volume":"90","author":"Vincent","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"B166","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","article-title":"New treatment guidelines for sjogren\u2019s disease","volume":"42","author":"Vivino","year":"2016","journal-title":"Rheumatic Dis. Clin. N. Am."},{"key":"B167","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrrheum.2010.118","article-title":"Pathogenetic mechanisms in the initiation and perpetuation of Sj\u00f6gren\u2019s syndrome","volume":"6","author":"Voulgarelis","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1002\/art.22176","article-title":"Overexpression of phosphorylated STAT-1alpha in the labial salivary glands of patients with Sj\u00f6gren\u2019s syndrome","volume":"54","author":"Wakamatsu","year":"2006","journal-title":"Arthritis & Rheumatism."},{"key":"B169","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s11655-020-3473-0","article-title":"Focus on effects of Chinese medicine on improving anxiety-depression and quality of life of patients with primary sjogren\u2019s syndrome","volume":"26","author":"Wu","year":"2020","journal-title":"Chin. J. Integr. Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sjogren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2023","journal-title":"Rheumatol. Oxf."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s10067-018-4064-8","article-title":"Monoclonal gammopathy in rheumatic diseases","volume":"37","author":"Yang","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"R170","DOI":"10.1186\/ar3493","article-title":"Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sj\u00f6gren\u2019s syndrome","volume":"13","author":"Yoshimoto","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"B173","doi-asserted-by":"publisher","first-page":"14135","DOI":"10.3390\/ijms232214135","article-title":"The future of targeted treatment of primary Sj\u00f6gren\u2019s syndrome: a focus on extra-glandular pathology","volume":"23","author":"Zeng","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1126421","DOI":"10.3389\/fimmu.2023.1126421","article-title":"B cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor-based therapy?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.tripleo.2010.01.006","article-title":"Expression of Toll-like receptors 7, 8, and 9 in primary Sj\u00f6gren\u2019s syndrome","volume":"109","author":"Zheng","year":"2010","journal-title":"Oral Surg. oral Med. oral pathology, oral radiology, Endod."},{"key":"B176","doi-asserted-by":"publisher","first-page":"602823","DOI":"10.3389\/fimmu.2020.602823","article-title":"CD8(+) T lymphocytes: crucial players in sjogren\u2019s syndrome","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1377055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T04:32:06Z","timestamp":1715920326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1377055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":176,"alternative-id":["10.3389\/fphar.2024.1377055"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1377055","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"article-number":"1377055"}}